Arch Venture Partners Xii, LLC
10% 持股人
Arch Venture Partners XII, LLC is a Delaware-incorporated limited liability company (CIK: 0001979548) serving as the general partner of ARCH Venture Partners XII, L.P., the investment vehicle associated with ARCH Venture Fund's XII, which closed at $2.975 billion in June 2022 to fund early-stage biotechnology companies focused on breakthrough technologies in areas like neurology, oncology, and mental health.[[1]](https://sparkco.ai/blog/arch-venture-partners)[[4]](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-2-975-billion-fund-xii-to-create-and-fund-early-stage-biotechnology-companies-301577375.html)[[5]](https://www.sec.gov/Archives/edgar/data/2040807/000095017025011345/0000950170-25-011345-index.htm)[[7]](https://www.archventure.com/arch-venture-partners-announces-2-975-billion-fund-xii-to-create-and-fund-early-stage-biotechnology-companies/) As a corporate insider and 10% owner of Neumora Therapeutics, Inc. (NMRA), it has engaged in recent trading activities related to the company's shares.[[2]](https://www.gurufocus.com/insider/235757/arch-venture-partners-xii,-l.p.)[[8]](https://www.nasdaq.com/market-activity/insiders/arch-venture-partners-xii-llc-1270763)
Arch Venture Partners XII, LLC operates within the broader ARCH Venture Partners ecosystem, a Chicago-based venture capital firm founded in 1986, renowned for co-founding and investing in over 130 active early-stage companies in life sciences, biotechnology, and deep-tech from top research institutions.[[1]](https://sparkco.ai/blog/arch-venture-partners)[[3]](https://www.archventure.com) The firm, with assets under management exceeding $10 billion, is led by managing directors including Keith Crandell, who signs on behalf of the entity, alongside co-founders Robert Nelsen and Kristina Burow.[[1]](https://sparkco.ai/blog/arch-venture-partners)[[4]](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-2-975-billion-fund-xii-to-create-and-fund-early-stage-biotechnology-companies-301577375.html)[[6]](https://www.sec.gov/Archives/edgar/data/1906837/000107261323000508/arch-sch13d_18764.htm) ARCH emphasizes partnering with scientists to commercialize disruptive science, providing not just capital but operational support in company building and leadership assembly.[[1]](https://sparkco.ai/blog/arch-venture-partners)[[4]](https://www.prnewswire.com/news-releases/arch-venture-partners-announces-2-975-billion-fund-xii-to-create-and-fund-early-stage-biotechnology-companies-301577375.html)
查看完整内部人档案 →